ClinVar Miner

Submissions for variant NM_024675.4(PALB2):c.12dup (p.Pro5fs)

dbSNP: rs879254062
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000235308 SCV000293344 pathogenic not provided 2022-08-15 criteria provided, single submitter clinical testing Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 29922827, 27469594)
Invitae RCV000686286 SCV000813798 pathogenic Familial cancer of breast 2023-11-05 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Pro5Serfs*8) in the PALB2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PALB2 are known to be pathogenic (PMID: 17200668, 17200671, 17200672, 24136930, 25099575). This variant is present in population databases (no rsID available, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 27469594). This variant is also known as c.12_13insT. ClinVar contains an entry for this variant (Variation ID: 246045). For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV001010853 SCV001171107 pathogenic Hereditary cancer-predisposing syndrome 2022-06-17 criteria provided, single submitter clinical testing The c.12dupT pathogenic mutation, located in coding exon 1 of the PALB2 gene, results from a duplication of T at nucleotide position 12, causing a translational frameshift with a predicted alternate stop codon (p.P5Sfs*8). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Color Diagnostics, LLC DBA Color Health RCV001010853 SCV001344281 pathogenic Hereditary cancer-predisposing syndrome 2019-08-21 criteria provided, single submitter clinical testing This variant inserts 1 nucleotide in exon 1 of the PALB2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. Computational splicing tools suggest that this variant may not impact RNA splicing. To our knowledge, functional assays have not been performed for this variant. This variant (also known as c.12_13insT in the literature) has been reported in an individual affected with breast cancer (PMID: 27469594). This variant has been identified in 1/247574 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of PALB2 function is a known mechanism of disease. Based on available evidence, this variant is classified as Pathogenic.
Myriad Genetics, Inc. RCV000686286 SCV004187521 pathogenic Familial cancer of breast 2023-09-05 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV004525908 SCV005039462 pathogenic Hereditary breast ovarian cancer syndrome 2024-03-12 criteria provided, single submitter clinical testing Variant summary: PALB2 c.12dupT (p.Pro5SerfsX8) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 4e-06 in 247574 control chromosomes. c.12dupT has been reported in the literature in individuals affected with Hereditary Breast And Ovarian Cancer Syndrome. These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. ClinVar contains an entry for this variant (Variation ID: 246045). Based on the evidence outlined above, the variant was classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.